期刊文献+

来曲唑内分泌治疗绝经后受体阳性转移性乳腺癌疗效观察 被引量:8

暂未订购
导出
摘要 目的观察来曲唑治疗绝经后受体阳性转移性乳腺癌的疗效。方法回顾性分析2008年5月至2011年7月合肥医学院附属医院肿瘤医院收治的32例有远处转移的晚期乳腺癌患者采用内分泌治疗的临床资料,并进行分析总结。结果有效评价病例32例,CR1例,PR13例,有效率为43.7%。其中ER及PR(+)组有效率为60%,ER或PR(+)组有效率为29.4%;Her-2不表达组有效率为66.7%,Her-2表达组有效率为14.3%;内脏器官转移组有效率为15.4%,其它部位转移组有效率为63.2%。不良反应恶心发生率:ER及PR(+)组有4例,ER或PR(+)组有2例;Her-2不表达组有5例,Her-2表达组有5例;内脏器官转移组有6例,其它部位转移组无恶心反应。头痛发生率:ER及PR(+)组有3例,ER或PR(+)组有1例;Her-2不表达组及表达组各有2例;内脏器官转移组有4例,其它部位转移组均无头痛反应。结论来曲唑对ER或PR阳性的绝经后转移性乳腺癌患者的疗效肯定,不良反应轻微,患者能够耐受。
出处 《合肥医学院学报》 2013年第3期251-253,共3页 Journal of Zunyi Medical University
  • 相关文献

参考文献9

  • 1范宇,付丽.雌激素受体与乳腺癌[J].诊断病理学杂志,2007,14(2):81-85. 被引量:10
  • 2Petz L N,Ziegler S,Schuhz J R, et al. Differential regu- lation of the human progesterone receptor gene through an estrogen response elemem half site and spl sites [ J ]. J Steroid Biochem Mol Biol, 2004,88 (2) : 113 - 122.
  • 3Thtirlimann B, Keshaviah A. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer [J]. N Engl J Med,2005,353(26):2747 -2757.
  • 4Forbes J F. The use of early adjuvant aromatase inhibitor therapy: contributions from the BIG 1 -98 letrozole trial [ J ]. Semin Oncol,2006,33 ( suppl 2) : 2 - 7.
  • 5Rouzier R,Extra J M, Carton M, et al. Primary chemother- apy foroperable breast Cancer: incidence and prognostic significance of ipsilateral breast tumor recurrence after breast - conserving surgery [ J ]. J Clin Oncol, 2001,19 (18) :3828 -3835.
  • 6Park C C, Mitsumori M, Nixon A, et al. Outcome at 8 years after breast conserving surgery and radiation therapy for invasive breast cancer: influence of margin status and sys- temic therapy on local recurrence [ J]. J Clin Oncol, 2000,18(8) :1668 - 1675.
  • 7程凯,徐珽,胡海波,唐尧.来曲唑治疗绝经后妇女乳腺癌疗效的系统评价[J].中国药房,2010,21(14):1302-1305. 被引量:6
  • 8徐兵河,孙燕,宋恕平,盛立军,王萍辉,侯媛淑,胡春宏,韩丽,熊建萍.来曲唑一线治疗绝经后妇女晚期乳腺癌[J].中国新药杂志,2002,11(9):722-724. 被引量:7
  • 9Jukkola A, Bloigu R, Soini Y, et al. c - erbB - 2 positivity is a factor for poor prognosis in breast cancer and poor re- sponse to hormonal or chemotherapy treatment in advanced disease [ J ]. Eur J Cancer,2001,37 (3) :347 - 354.

二级参考文献53

  • 1刘恒戈.内分泌药物治疗乳腺癌的临床应用进展[J].中国药房,2005,16(10):791-793. 被引量:6
  • 2王晓红,章爱斌,倪俊,顾凤元.来曲唑在绝经后乳腺癌患者新辅助化疗中的应用价值探讨[J].浙江医学,2006,28(6):502-503. 被引量:9
  • 3沈恩超,王水,凌立君,张建新.芳香化酶抑制剂在乳腺癌内分泌治疗中的研究进展[J].江苏大学学报(医学版),2006,16(5):456-458. 被引量:9
  • 4Higgins J, Green S.Cochrane Handbook for Systematic Reviews oflnterventions[M].Published by John Wiley-Sons Ltd., 2008, Part2 : Table 8.5.c.
  • 5Koeberle D, Thuerlimann B. Letrozole as upfront endocrine therapy for postmenopausal women with hormone-sensitive breast cancer: BIG 1-98[J]. Breast Cancer Res Treat, 2007,105( 1 ) : 55.
  • 6Mouridsen H, Gershanovich.M, Sun Y, et al.Phase Ⅲ study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women:analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group[J]. J Clin Oncol, 2003, 21(11):2 101.
  • 7Eiermann W, Appfelstaedt J.Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study[J].Ann Oncol,2001,12(11):1 527.
  • 8Gibson LJ, Dawson CL, Lawrence D J, et al.Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women[J]. The Cochrane Collaboration, 2008,3 : 1.
  • 9Rubens RD. Advanced breast cancer: reassessing hormonal therapy [M]. New York: Parthenon Publishing, 1996.21-30.
  • 10Lamb HM, Adkins JC. Letrozole-a reviews of its use in postm-enopausal women with advanced breast cancer [J]. Drugs, 1998,56(6): 1125 - 1129.

共引文献19

同被引文献79

引证文献8

二级引证文献46

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部